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Background/Aims: The relationships between serum pro-
calcitonin, inflammatory bowel disease (IBD) and intestinal 
Behçet’s disease (BD) have not been completely determined. 
We aimed to evaluate the usefulness of measuring serum 
procalcitonin levels to assess disease activity and infection 
stage in patients with IBD and intestinal BD. Methods: We 
retrospectively analyzed clinical data from 129 patients with 
IBD and intestinal BD for whom serum procalcitonin and C-
reactive protein (CRP) levels were measured between Janu-
ary 2006 and February 2013. Results: The median serum 
procalcitonin levels in the IBD and intestinal BD with septic 
shock or sepsis (n=8), with localized infection (n=76), and 
without infection (n=45) were 3.46 ng/mL (range, 0.17 to 
63.66 ng/mL), 0.22 ng/mL (range, 0.05 to 140.18 ng/mL), 
and 0.07 ng/mL (range, 0.00 to 31.50 ng/mL), respectively 
(p=0.001). The serum CRP levels in the IBD and intestinal 
BD patients did not differ according to the infection stage. 
Variations in serum procalcitonin levels were not observed 
in the IBD and intestinal BD patients with different disease 
activities. Conclusions: Serum procalcitonin levels may not 
be affected by IBD and intestinal BD activity itself, although 
they may be affected by concomitant infection. Serum pro-
calcitonin measurements could be more useful than CRP 
in determining the infection stage that reflects the severity 
of infection in IBD and intestinal BD patients. (Gut Liver 
2016;10:574-580)
Key Words: Procalcitonin; Inflammatory bowel disease; Intes-
tinal Behçet’s disease; Infection; Disease activity
INTRODUCTION
Inflammatory bowel disease (IBD) and intestinal Behçet’s 
disease (BD) are chronic intestinal inflammatory disorders 
with repeated remissions and relapses and they have complex 
causes.1-3 Deterioration in disease stage of IBD can occur due 
to disease aggravation itself, but it is often attributed to com-
bined infection with a pathogenic organism.4 Similar to IBD, 
intestinal BD is also a chronic intestinal inflammatory disease 
with repeated episodes of relapse and remission.5 Early detec-
tion and treatment of infection can prevent infection-related 
disease exacerbation and serious complications such as septic 
shock in patients with IBD and intestinal BD. These infectious 
complications are facilitated by the use of immunomodulators 
or biologics. However, in patients with IBD, clinical manifesta-
tions associated with bacterial infections and disease exacerba-
tion cannot be easily differentiated from time to time.6 Reliable 
and rapid biomarkers for infection might help early detection 
and treatment, which might induce good prognosis of infec-
tion in IBD and intestinal BD patients. Procalcitonin, a precur-
sor of calcitonin, is known to be an acute-phase protein and a 
good marker of bacterial infection and sepsis.7-9 Procalcitonin 
is mainly produced by the thyroid C cells.10 In infection, procal-
citonin is produced by extra thyroidal organs including liver, 
intestines, monocytes, and some neuroendocrine cells.10,11 In pa-
tients with bacterial sepsis, serum procalcitonin might be a more 
useful marker for assessing the bacterial infection stage with 
higher specificity and sensitivity than C-reactive protein (CRP).12 
However, the usefulness of serum procalcitonin measurement 
in identifying infection stage in IBD and intestinal BD patients 
remains unanswered. Also, the relationship between disease 
activity and serum procalcitonin level in IBD and intestinal BD 
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patients is yet to be determined. Therefore, we aimed to evaluate 
the usefulness of measurement of serum procalcitonin and CRP 
levels in the infected and noninfected states of patients with IBD 
and intestinal BD. We also investigated the serum procalcitonin 
level as markers for disease activity of IBD and intestinal BD.
MATERIALS AND METHODS
1. Study subjects and measurement of procalcitonin
Between January 2006 and February 2013, our retrospective 
study included a total of 129 patients with IBD and intestinal 
BD at Severance Hospital in Korea whose serum procalcitonin 
and CRP levels were measured. According to the diagnostic 
criteria for IBD, the patients were diagnosed as ulcerative colitis 
(UC), Crohn’s disease (CD), or intestinal BD.13,14 We retrospec-
tively analyzed their clinical data at the time when their serum 
procalcitonin levels were measured. The exclusion criteria were 
patients with previous other systemic inflammatory diseases, 
malignancies, pregnant women, adolescents and a history 
of abdominal operation. The serum procalcitonin level was 
measured in patients with IBD and intestinal BD using a com-
mercially available enzyme-linked fluorescent assay (bioMer-
ieux Co., Marcy L’Etoile, France). The normal range of serum 
procalcitonin level was 0 to 0.5 ng/mL. The serum CRP levels 
were measured by the particle enhanced immunoturbidimetric 
assay (Roche Diagnostics GmbH, Mannheim, Germany). The 
normal range of CRP level was 0 to 8 mg/L. The Institutional 
Review Board of Severance Hospital at Yonsei University Col-
lege of Medicine approved the study protocol (approval number: 
4-2014-1012).
2. Determination of disease activity
According to the American College of Gastroenterology, the 
severity of UC was categorized as remission, mild, moderate, 
and severe disease.15 The severity of CD was categorized as re-
mission, mild-moderate, moderate-severe, and severe-fulminant 
disease.16 The disease activity of intestinal BD was assessed 
using the disease activity index for intestinal Behçet’s disease 
(DAIBD).17 The DAIBD consists of eight categories such as gen-
eral well-being, fever, extraintestinal manifestations, abdominal 
pain, abdominal mass, abdominal tenderness, intestinal compli-
cation, and the number of liquid stools, and it ranges in value 
from 0 to 325.
3. Definition of infectious complications 
Bacterial infection was diagnosed by identification of patho-
genic bacteria from suspicious specimens6 or if the clinical 
characteristics of patients were clearly associated with infection. 
Sepsis was defined as the presence of infection combined with 
signs of the systemic inflammatory response syndrome (SIRS). 
SIRS was diagnosed when two or more of the following condi-
tions were present:18 (1) temperature >38oC or <36oC; (2) heart 
rate >90 beats per minute; (3) respiratory rate >20 breaths per 
minute or PaO2 <32 mm Hg; and (4) white blood cell count 
>12,000/μL, <4,000/μL, or >10% immature (band) forms. Septic 
shock was defined as sepsis-induced hypotension in spite of 
adequate fluid supply combined with organ dysfunction or hy-
poperfusion abnormalities.19 
4. Statistical analysis
Nonparametric continuous variables were compared using the 
Kruskal-Wallis and Mann Whitney U tests. Receiver operating 
characteristic (ROC) curve was reconstructed and area under the 
curves (AUC; with 95% confidence interval [CI]) of procalcitonin 
and CRP were compared. All statistical analyses were performed 
using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). In all 
cases, p-values <0.05 were considered statistically significant.
RESULTS 
1. Types of IBD and infection
Among the 129 patients, the number of patients with UC, 
Table 1. Clinical Characteristics of Patients according to the Disease Type 
Characteristic UC (n=20) CD (n=38) Intestinal BD (n=71) p-value
Age, yr 41.9±18.2 28.8±10.4 43.18±13.00 <0.001
Male/female 14 (70.0)/6 (30.0) 21 (55.3)/17 (44.7) 25 (35.2)/46 (64.8) 0.010
Disease activity 0.079
    Active state 5 (25.0) 4 (10.5) 21 (29.6)
    Inactive state 15 (75.0) 34 (89.5) 50 (70.4)
Therapy
    5-ASA 10 (50.0) 17 (44.7) 19 (26.8) 0.061
    Azathioprine 2 (10.0) 14 (36.8) 7 (23.9) 0.075
    Steroid 8 (40.0) 13 (34.2) 39 (54.9) 0.097
    TNF-α blocker 3 (15.0) 7 (18.4) 4 (5.6) 0.100
Data are presented as mean±SD or number (%).
UC, ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; TNF-α, tumor necrosis factor α.
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CD, and intestinal BD was 20, 38, and 71, respectively (Table 1). 
The infection sites were respiratory tract in 18 patients (21.4%), 
gastrointestinal tract in 50 patients (59.5%), genitourinary tract 
in four patients (4.8%), skin in 10 patients (11.9%), heart in one 
patient (1.2%), and bone in one patient (1.2%).
2. Serum procalcitonin and CRP levels according to the 
stage of infection and disease activity
The serum procalcitonin levels were increased as the infection 
became severe in patients with IBD and intestinal BD. The me-
dian (minimum–maximum) serum procalcitonin levels in IBD 
and intestinal BD patients with septic shock or sepsis, localized 
infection, and no infection were 3.46 (0.17 to 63.66) ng/mL, 0.22 
(0.05 to 140.18) ng/mL, and 0.07 (0.00 to 31.50) ng/mL, respec-
tively (p=0.001) (Table 2). However, the serum CRP levels in IBD 
and intestinal BD patients were not different according to the 
stage of infection (Table 3). The median (minimum–maximum) 
serum procalcitonin and CRP levels in patients with IBD and in-
testinal BD were not different according to the stage of disease 
activity as shown in Table 4.
3. Serum procalcitonin and CRP levels according to the 
stage of infection at the same disease activity level 
To determine the exact relationship between stage of infec-
tion and serum procalcitonin, the serum procalcitonin levels 
were compared in IBD and intestinal BD patients with the 
same level of disease activity. The median serum procalcitonin 
(Table 5) and CRP levels (Table 6) were not significantly differ-
ent in patients with IBD according to the stage of infection at 
the same disease activity level. However, the median serum pro-
calcitonin levels in active intestinal BD patients were increased 
significantly according to the stage of infection (Table 5). The 
median (minimum–maximum) serum procalcitonin levels in ac-
tive intestinal BD patients with septic shock or sepsis, localized 
infection, and no infection were 13.57 (0.17 to 63.6) ng/mL, 
0.25 (0.05 to 48.8) ng/mL, and 0.21 (0.0 to 31.50), respectively 
(p=0.020). 
4. ROC curve, sensitivity, specificity, positive and negative 
predictive values of procalcitonin and CRP
ROC curves were plotted to evaluate the diagnostic power of 
the procalcitonin and CRP for infection status. In Fig. 1, ROC 
curve of (A) procalcitonin and (B) CRP were reconstructed. The 
AUC (95% CI) of procalcitonin and CRP were 0.636 (0.539 to 
0.732) and 0.542 (0.437 to 0.646), respectively. In Table 7, the 
sensitivity, specificity, positive and negative predictive val-
ues of procalcitonin were 40.5%, 84.4%, 82.9%, and 84.4%, 
respectively. The sensitivity, specificity, positive and negative 
Table 2. Categories of Infectious Complications in Patients with Inflammatory Bowel Disease and Intestinal Behçet’s Disease 
No. of patients (n=129)
UC (n=20) CD (n=38) Intestinal BD (n=71)
Septic shock or sepsis 0 1 (2.6) 7 (9.8)
Infection 9 (45) 25 (65.8) 42 (59.2)
No infection 11 (55) 12 (31.6) 22 (31)
Data are presented as number (%).
UC, ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease.
Table 3. Serum Procalcitonin Levels according to the Stage of Infection
Septic shock or sepsis (n=8) Infection (n=76) No infection (n=45) p-value
Procalcitonin, ng/mL 3.46 (0.17–63.66) 0.22 (0.05–140.18) 0.07 (0.00–31.50) 0.001
CRP, mg/L 64.73 (11–447) 47.97 (0–343) 40.78 (0–323) 0.284
Data are presented as the median (minimum–maximum).
CRP, C-reactive protein.
Table 4. Relationship between the Procalcitonin Level and Disease Activity in Patients with Inflammatory Bowel Disease and Intestinal Behçet’s 
Disease 
UC (n=20) CD (n=38) Intestinal BD (n=71)
Remission (n=5) Active (n=15) p-value Remission (n=4) Active (n=34) p-value Quiescent (n=21) Active (n=50) p-value
Procalcitonin, ng/mL 0.05 (0–3.84) 0.15 (0–10.79) 0.553 0.07 (0.04–0.08) 0.11 (0–140.18) 0.521 0.20 (0–11.85) 0.32 (0–63.66) 0.452
CRP, mg/L 47.74 (0–116) 22 (1–191) 0.735 26.35 (0–268) 51.5 (1–197) 0.536 59.04 (0–287) 49.51 (0–447) 0.504
Data are presented as the median (minimum–maximum).
UC, ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; CRP, C-reactive protein.
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predictive values of CRP were 84.5%, 17.8%, 65.7%, and 38.1%, 
respectively. 
DISCUSSION
In patients with IBD, symptoms and laboratory data in bacte-
rial infections and disease flare up are similar and it is often dif-
ficult to differentiate between them.6 It is important to differenti-
ate bacterial infections from disease flare up because treatments 
according to the disease stage are totally opposite. Especially, in 
case of infection, early detection and treatment of infection can 
lead to good prognosis in patients with IBD. However, disease 
flare up necessitates the use of more powerful immunomodula-
tory drugs which can potentially exacerbate the infection. If the 
treatment is not performed accordingly, it could lead to rapid 
deterioration of general condition of the patients. Therefore, a 
reliable marker for discriminating bacterial infections and dis-
ease flares is needed. Procalcitonin is an acute phase protein 
whose level is increased in response to inflammatory stimuli, 
including infections.20,21 The serum procalcitonin level above 0.5 
ng/mL is used to discriminate infections from noninfection.22 
Serum procalcitonin is known to be a good marker for detecting 
bacterial infections and sepsis.7-9 The serum procalcitonin level 
can be measured quickly and it helps to make an early diagno-
sis in an emergent situation such as systemic inflammation or 
septic shock.10 In a meta-analysis, the sensitivity of procalcito-
nin ranged from 42% to 100% and the specificity of procalcito-
nin ranged from 48% to 100%, as a diagnostic test for sepsis.10 
There are several reports suggesting that procalcitonin is a 
good biomarker for infection.7-9,23-25 Traditional inflammatory 
biomarkers such as CRP, leukocytes, and erythrocyte sedimenta-
tion rate could not help to decide treatment for discriminating 
bacterial infection and flare up of IBD.6,26-28 Serum procalcitonin 
had better sensitivity and specificity than CRP for the exact 
diagnosis of bacterial infections.6,12,29 In our report also, only 
serum procalcitonin levels were increased in infection stage of 
patients with IBD and intestinal BD. In this study, to determine 
the exact relationship between stage of infection and serum 
procalcitonin, the serum procalcitonin levels were compared in 
IBD and intestinal BD patients with the same level of disease 
activity. The median serum procalcitonin levels were increased 
significantly in only active intestinal BD patients according to 
the stage of infection. However, the serum procalcitonin levels 
were not changed significantly in IBD and inactive intestinal 
BD patients according to the stage of infection. Moreover, CRP 
levels were not increased significantly in patients with IBD and 
intestinal BD according to the stage of infection. One previous 
report showed that serum procalcitonin was a good diagnostic 
marker for differentiating IBD and self-limited colitis.30 How-
ever, in this previous report, the authors did not investigate the 
relationship between the stage of infection and serum procalci-
tonin in IBD. Therefore, our report is unique because we evalu-
ated the relationship between the stage of infection and serum 
procalcitonin level in patients with IBD and intestinal BD. In 
A
0 0.2 0.4 0.6 0.8
1.0
0.8
0.6
0.4
0.2
1.0
S
e
n
s
it
iv
it
y
1-Specificity
0
0 0.2 0.4 0.6 0.8
1.0
0.8
0.6
0.4
0.2
1.0
S
e
n
s
it
iv
it
y
1-Specificity
0
B
Fig. 1. Receiver operating characteristic curves for (A) procalcitonin and (B) C-reactive protein (CRP) were reconstructed. The areas under the 
curve (95% confidence interval) of procalcitonin and CRP were 0.636 (0.539 to 0.732) and 0.542 (0.437 to 0.646), respectively. 
Table 7. Sensitivity, Specificity and Positive and Negative Predictive Values of Procalcitonin and C-reactive Protein 
Sensitivity Specificity Positive predictive value Negative predictive value
Procalcitonin, % 40.5 84.4 82.9 84.4
CRP, % 84.5 17.8 65.7 38.1
CRP, C-reactive protein.
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our study, the serum procalcitonin level was increased after 
infection in patients with IBD and intestinal BD. Especially, in 
cases with severe infection like septic shock or sepsis, the serum 
procalcitonin levels were 49 times higher compared to those in 
cases without infection 3.46 (0.17 to 63.66) ng/mL vs 0.07 (0.00 
to 31.5) ng/mL. However, in cases of infection without sepsis, 
the serum procalcitonin levels were only three times higher 
compared to those in cases without infection (0.22 ng/mL [range, 
0.05 to 140.18 ng/mL] vs 0.07 ng/mL [range, 0.00 to 31.5 ng/
mL]). Based on our results, we drew a conclusion that elevation 
of serum procalcitonin level might be induced in proportion to 
the severity of infection in IBD patients. According to our re-
sults, serum procalcitonin could be a useful marker for detecting 
severe infection like septic shock or sepsis than merely minor 
localized infection. 
With respect to the disease activity in IBD, there are inconsis-
tent results about serum procalcitonin as a marker for disease 
activity of IBD. In one study, although the serum procalcitonin 
level was in the normal range, it was positively related with 
disease activity in patients with IBD.30-32 In another study, serum 
procalcitonin was shown to be correlated with UC activity.31,32 
However in a separate study, the serum procalcitonin level was 
not related with disease activity in patients with UC,11 CD,33 and 
intestinal BD.34 These inconsistent results about serum procal-
citonin as a marker for disease activity of IBD might be due to 
different disease activity indices used in different studies and 
different combined infections. CRP has been known to be a 
reliable marker for assessing disease activity in patients with 
IBD11 and intestinal BD.34 In our report, CRP level could not 
differentiate between inactive and active disease activity when 
the disease was combined with infection in patients with active 
IBD and intestinal BD. Based on our results, elevated serum pro-
calcitonin might have an important role of a useful marker for 
detecting infection in patients with IBD and intestinal BD. 
Our study has some key strengths. First, serum procalcitonin 
levels were compared according to the severity of infection 
categorized as no infection, localized infection, and sepsis or 
septic shock. We also sought to determine the exact relationship 
between stage of infection and serum procalcitonin by evaluat-
ing serum procalcitonin levels in patients with the same level of 
disease activity of IBD and intestinal BD. Second, this is the first 
study to compare the serum procalcitonin levels in intestinal BD 
patients. Third, based on our study, it could be suggested that a 
higher procalcitonin level might reflect the severity of infection. 
However, there were a few limitations to our study. First, the 
number of patients included in our study was relatively small. 
In particular, the number of patients in inactive state of IBD 
and intestinal BD was very small, which might have hampered 
from drawing the concrete conclusion on the role of procal-
citonin level in inactive disease stage. Second, patients with 
IBD were enrolled retrospectively from a single tertiary center, 
which might have caused an inevitable selection bias. Third, we 
measured the procalcitonin level only before antibiotic treat-
ment. We could not compare the procalcitonin level before and 
after antibiotic treatments to know the relationship between 
the change in procalcitonin and infection. Fourth, although the 
median procalcitonin level in patients with infection was higher 
than that in patients without infection, it was 0.22 still falling 
into normal range. Finally in this study, we did not specifically 
investigate the relationship between viral infections and disease 
flare-up.
In conclusion, the serum procalcitonin level may not be af-
fected by IBD activity, but by combined infection. Measurement 
of serum procalcitonin level can be useful in differentiating in-
fectious complications in IBD and intestinal BD patients experi-
encing disease flare up. A higher serum procalcitonin level may 
reflect the severity of infection. Therefore, serum procalcitonin 
level can be a candidate biomarker for assessing the infection 
stage in IBD or intestinal BD patients.
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